Literature DB >> 25070816

L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.

X L Shu1, X L Liu, J X Zhong, J Liu.   

Abstract

OBJECTIVE: Arginine deiminase (ADI) and L-arginine (L-Arg) can act as anti-tumor agents in-vitro and in-vivo. However, the mechanism of ADI and L-Arg as anti-tumor agents has not been clearly shown.
MATERIALS AND METHODS: With the goal of understanding the role of ADI and L-Arg in inhibition of cell growth, we used the Ramos human lymphoma cell line, which is known to be ADI-sensitive, and observed the p53 and NF-κBp65 protein expression after ADI and arginine treatment. After determining an optimal experimental ADI concentration (0.01 U/ml), we studied the effects of ADI treatment, when combined with different concentrations of L-arginine (control, ADI only, ADI with 10 mM/ml Arg, ADI with 30 mM/ml Arg, and ADI with 50 mM/ml Arg). An MTT assay was used to assess cell survival after treatment, Western blot analysis to determine the levels of the NF-κBp65, p53 and NO mediators and nitric oxide assays were used to determine nitrite levels. RESULTS AND
CONCLUSIONS: L-arginine enhanced ADI-induced inhibited cell growth through expression of NF-κBp65 and p53 in a dose-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25070816

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  1 in total

1.  Graphene Functionalized with Arginine Decreases the Development of Glioblastoma Multiforme Tumor in a Gene-Dependent Manner.

Authors:  Ewa Sawosz; Sławomir Jaworski; Marta Kutwin; Krishna Prasad Vadalasetty; Marta Grodzik; Mateusz Wierzbicki; Natalia Kurantowicz; Barbara Strojny; Anna Hotowy; Ludwika Lipińska; Joanna Jagiełło; André Chwalibog
Journal:  Int J Mol Sci       Date:  2015-10-23       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.